• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Trending Tickers: MNK, FTR, DISCA, CVS

Markets were falling as oil prices continued their two-month descent below $40 a barrel.
By JAMES PASSERI Aug 02, 2016 | 01:16 PM EDT
Stocks quotes in this article: MNK, FTR, CVS, DISCA, LBTYK

U.S. markets were down in midday trading Tuesday, with the S&P 500 and Dow Jones industrials down 0.8% and 0.6%, respectively. Meanwhile, oil continued its two-month slide, falling below $40 a barrel, down roughly 1.4% to $39.50 a barrel in afternoon trading, based on U.S. benchmark West Texas Intermediate.

Shares of Mallinckrodt (MNK) were climbing about 13% after the Dublin-based drugmaker topped earnings expectations and hiked its 2016 earnings forecast to a range of $8.50 to $8.80, from prior guidance of $8.15 to $8.50. (Mallinckrodt shares are still down roughly 39% over the past 12 months.) The drugmaker also posted quarterly earnings per share of $2.20 Tuesday, about 9% higher than consensus estimates, while sales of $971 million for the period topped forecasts by about 5%.

CEO Mark Trudeau said in a statement that much of the company's success in the quarter stems from the growth of a variety of its specialty drugs. "We continue to generate compelling new data and clinical evidence for key brands, and are working to bring this data to new physicians and patients -- clear evidence that our Acquire to Invest strategy is creating performance momentum," he added.

Short seller Andrew Left, the founder of Citron Research, has been vocal about his bearish view on Mallinckrodt this year, going so far as to promise in May to give $1 million to a selected charity if Mallinckrodt did a proper clinical study on its premiere drug, Acthar.

Meanwhile, Frontier Communications (FTR) shares were down about 5% after the Stamford, Conn.-based telephone company fell short of analyst expectations in its quarterly sales numbers, which were released with earnings after the closing bell Monday. Frontier booked sales of $2.61 billion vs. consensus estimates of $2.73 billion, as an earnings loss of $0.02 per share beat forecasts of $0.03. The company pointed to a temporary suspension of marketing acquisitions for much of the slowdown but its CEO Daniel McCarthy said on an earnings call with analysts that the Frontier is "now back to a typical level of marketing."

Discovery Communications (DISCA) shares gained about 6% in midday trading after posting earnings per share in the second quarter of $0.71, topping consensus forecasts of $0.58, while sales of $1.71 billion were in line with estimates. "A key element of Discovery's growth profile is our continued success in securing long cycle distribution agreements that provide for steady and predictable revenue growth and the optionality for windowing our content on existing and new platforms," CEO David Zaslav said on an earnings call with analysts. Management also unveiled a long-term affiliate deal with Liberty Global (LBTYK) , one of its largest distribution partners.

CVS Health (CVS) shares were also 5% on an earnings beat and raised 2016 earnings guidance to a range of $5.81 to $5.89 vs. consensus estimates of $5.82. The company also booked earnings per share of $1.32 vs. forecasts of $1.30, while sales of $43.7 billion fell short of expectations of $44.3 billion for the quarter. (CVS Health is a holding of the Trifecta Stocks model portfolio.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from owning individual securities.

TAGS: Investing | U.S. Equity | Healthcare | Telecom Services | Earnings | Markets | Stocks

More from Healthcare

Boston Scientific Could Be Wicked Good in This Kind of Market

Brad Ginesin
May 24, 2022 2:13 PM EDT

Here's why this healthcare stock is a potential port in the storm for investors.

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:33 AM EDT PETER TCHIR

    Thoughts Ahead of the Fed Minutes

    Recent economic and earnings issues are convincing...
  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login